Lindbrook Capital’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Lindbrook Capital’s Portfolio CYT Stock Details CYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,006	Closed	-$6.04K	–	2870
2024 Q1	$6.04K	Hold	2,006	–	–	﹤0.01%	1811
2023 Q4	$6.1K	Hold	2,006	–	–	﹤0.01%	1778
2023 Q3	$5.7K	Hold	2,006	–	–	﹤0.01%	1706
2023 Q2	$5.22K	Hold	2,006	–	–	﹤0.01%	1783
2023 Q1	$3.65K	Hold	2,006	–	–	﹤0.01%	1985
2022 Q4	$3.31K	Hold	2,006	–	–	﹤0.01%	2004
2022 Q3	$4K	Buy	2,006 +2,000	+33,333%	+$5.21K	﹤0.01%	1813
2022 Q2	$0	Buy	+6	New	+$15	﹤0.01%	2844

Lindbrook Capital's CYT Position: Q2 2024 in Review

Lindbrook Capital sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q2 2024, closing a stake of 2,006 shares — an estimated $6.04K sold.

Lindbrook Capital first reported a position in CYT in Q2 2022 and held it in 8 quarters. The position peaked at $6.1K in Q4 2023. 0 funds tracked by Wall St. Rank hold CYT as of Q2 2024.

Lindbrook Capital reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Lindbrook Capital sold 2,006 Cyteir Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $6.04K.
Lindbrook Capital first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2022 and held it in 8 quarters.
Lindbrook Capital's Cyteir Therapeutics, Inc. Common Stock position peaked at $6.1K in Q4 2023.
0 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Lindbrook Capital's 13F filing for Q2 2024, filed 31 Jul 2024.